ASCO 2026 Embargoed Virtual Press Briefing Tuesday May 26 — Late-Breaking Abstracts Pre-Meeting Reveal for Credentialed Media Ahead of May 29 Opening
ASCO will hold an embargoed virtual press briefing for credentialed media on Tuesday May 26 to preview Late-Breaking Abstracts being presented during the Annual Meeting that opens Friday May 29 in Chicago. Late-Breaking Abstracts are submitted after the standard abstract deadline and contain data that would not have been available at the regular submission cycle — typically the highest-impact data of the meeting. The briefing covers presentations across the full ASCO program including the peptide-oncology slate that landed in the May 21 abstract release: Bicycle Therapeutics' Duravelo-2 Phase 2 (65% ORR/58% BICR-confirmed), Avacta's AVA6000 Phase 1a/1b in salivary gland cancer (90% disease control rate), Sapience Therapeutics' lucicebtide Phase 2 GBM, BriaCell's Bria-IMT 16.6-month Phase 2 OS, Corbus Pharmaceuticals' CRB-701 Nectin-4 ADC, and Crinetics' CRN09682 SSTR2 NDC BRAVESST2. The May 26 embargo lifts late afternoon to feed press coverage into the Wednesday-Thursday cycle.